Skip to content

Assessment of Myocardial Injury in Simultaneous Pancreas and Kidney Transplantation

Assessment of Myocardial Injury in Recipients of Simultaneous Pancreas and Kidney Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03904485
Acronym
AMI-SPK
Enrollment
50
Registered
2019-04-05
Start date
2019-04-01
Completion date
2021-04-01
Last updated
2019-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Cardiomyopathy, Simultaneous Pancreas-kidney Transplantation

Keywords

SPK ,DCM,CMR

Brief summary

Diabetic cardiomyopathy( DCM) is a major complication of diabetes and is a common cardiovascular complication independent of coronary artery disease and hypertension.Trial to assess of myocardial injury in recipients of simultaneous pancreas and kidney transplantation by nuclear magnetic T2 mapping technology.

Detailed description

1. Evaluate the changes of myocardial injury before and after SPK by cardiac magnetic resonance imaging (CMR), 2. Evaluate the value of SPK in the repair of myocardial injury by comparing with the single renal transplant in recipients with diabetic nephropathy.

Interventions

RADIATIONcardiac magnetic resonance(CMR) T2 mapping

T2 value before transplant,3 month and 6month after transplant

Sponsors

Tianjin First Central Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. patients with type 2 diabetes were treated with SPK; 2.No definite history of cardiovascular diseases (such as congenital heart disease, coronary heart disease, cardiomyopathy or valvular heart disease, etc.); 3. Preoperative hemodialysis 4. No history of heart failure

Exclusion criteria

1. Contraindications in cardiac magnetic resonance imaging;2.poorly controlled hypertension;3.CMR examination revealed marked hypertrophy of the left ventricular myocardium

Design outcomes

Primary

MeasureTime frameDescription
Assessment of myocardial injury1yearAssessment of myocardial injury between two groups

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026